Evonik Keeps BASF Talking Without Talking Price
Published on 11/01/2026 at 15:21 | Editorial boerse-global.de
Evonik's board has drawn a line that investors would do well to read carefully. It will sit down with BASF for a confidential, purely informational exchange — but that is a channel for understanding, not an invitation to negotiate a sale. The distinction matters because it separates two very different questions now hanging over the stock: what a deal might be worth, and what Evonik is worth on its own.
BASF lifted its offer to EUR 24.00 per Evonik share on 23 October, according to Handelsblatt, structuring it as an all-cash bid with commitments to preserve sites and jobs. Evonik shares closed Friday at EUR 21.06, below that headline number. The gap is not a locked-in return. It can only be captured if a transaction actually materialises, and the board's refusal — grounded in what Reuters reported as a lack of industrial logic — means price is not the only sticking point. A purely arithmetic reading of the spread misses the strategic dispute underneath it.
Two Paths, Two Sets of Demands
BASF met the rejection with incomprehension on Friday, Reuters reported, pointing to its improved offer and its pledges on employees and locations. That leaves a concrete valuation benchmark on one side of the table and a board committed to independence on the other, with no common negotiating ground established so far.
For shareholders, the choice is between the value of a possible transaction and the earnings prospects of a company charting its own course. Neither should be treated as guaranteed. The board's stated preference does not, by itself, settle the valuation question — the standalone case has to be measured against operating performance and the room Evonik has to develop.
Should investors sell immediately? Or is it worth buying Evonik?
Portfolio moves form part of that standalone story. Handelsblatt reported on 22 October that Evonik has been weighing larger US acquisitions for months, with specialty chemicals group Ashland among possible candidates. The review is at an early stage and no completion is assured. That makes it a strategic option, not a decided growth step — and size alone would be no argument for a deal. A credible investment case would have to show why an acquisition strengthens the independent path.
A Subsidiary With Its Own Mind
Internal interests add another layer. Reuters reported that management at Evonik subsidiary Syneqt came out in favour of independence on Tuesday, saying the business wants to find a new owner and preserve jobs permanently. That underlines how any restructuring would be more than a question of price; divergent strategic views could make execution harder.
Running a possible US acquisition alongside a potential takeover scenario also places different demands on capital allocation and corporate direction. While both remain open, investors should resist folding them into a single settled plan.
Evonik at a turning point? This analysis reveals what investors need to know now.
What November 3 Can and Cannot Settle
The next hard date is the Q3 2026 quarterly statement on 3 November. It can sharpen the economic case for or against independence — and, if the numbers convince, strengthen the board's hand with shareholders. Should they disappoint, the relative value of BASF's offer is likely to move back to centre stage. A well-founded alternative to a merger could also bolster Evonik's position in any later conversation, though that is a scenario, not a confirmed development.
What the report cannot do is resolve the takeover question by itself. Nor should the informational exchange with BASF be overread: no negotiations have been promised, and Reuters noted no deal or further increase follows from BASF's response. The genuine risk is that neither route ends up convincing investors — those betting solely on a deal depend on decisions that are not yet made, while those trusting only in independence must judge whether it stands up economically. The open channel does not dissolve that tension. The discipline for shareholders is to keep the two apart: assess operating progress through the business figures, and measure any transaction opportunity strictly against the procedural status actually reached.
Ad
Evonik Stock: New Analysis - 1 November
Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
